Top
Homeland Security Market ResearchUS COVID-19 Pandemic Mitigation Products Market – 2020-2024
US COVID-19 Market Cover
NEW

US COVID-19 Pandemic Mitigation Products Market - 2020-2024

22% to 25% of the cumulative 2020-2024 $1.7–2.2 Trillion Market

  • July 2020
  • 320
  • 185
    • 4950 $
    • 5950 $
    • 8950 $
    • 12000 $

    Small Businesses, Startups & Academia - Up to 50% Off

Quantity
IBM
Amazon
Sandia National Lab
HITACHI
Thales
Smiths Detection
Nuctech
Korea Internet & Security Agency
L3Harris
Huawei
Leidos
NEC
Toshiba
Mckinsey & Company
Deloitte

Want to customize this report?

If you purchase this report, you are entitled to a 30% discount towards customizing it, to better fit your market research and strategic needs. Our Custom Research and Industry Insights Department will work with you to better understand your information gaps and strategic needs and will provide you with a tailor-made market research report within a short period of time.

Why Choose Us?

30+ Years of Experience
We are a multidisciplinary team of homeland security and public safety industry experts with over 30 years of experience.
Gold Standard
With over 950 private sector clients (73% repeat customers), including major defense and security vendors, and Forbes Global 2000 companies, HSRC earned the reputation as the industry’s Gold Standard for Homeland Security & Public Safety Market Reports.
Tailored Research Services
Provide you with clear, actionable recommendations designed to empower decision making and to help you exploit emerging opportunities in the homeland security & public safety industries.
Information Security
Your personal information is safe and secure.

From: $4,950

Description

US COVID-19 Pandemic Mitigation Products Market – 2020-2024 Report

 

According to this most up-to-update analysis the U.S. is set to lead the Global market* with an annual market* share of 22% to 25% of the cumulative 2020-2024 $1.7–$2.2 Trillion market.

 

The U.S, is the leading nation in healthcare spending, resources, medical research and sophisticated medical care. The U.S. spends $3.3 trillion (Source: IMF, 2019) per year on healthcare, which is more than the combined expenditures of China, Japan, Germany, India, the United Kingdom, Italy, Brazil, Canada, Russia, South Korea, Spain, Australia, Mexico, Indonesia, the Netherlands, Saudi Arabia, Turkey and Switzerland ($3.24 trillion).

 

When compared directly to China, given the rivalry between the PRC and the USA, it might be important to note that China is very much still a developing country in the field of healthcare infrastructure and spending. China spends 23 times less than the U.S. in terms of per-capita health care expenses ($430 to $10,100) and has 9.6 times (2019 Data) fewer intensive care unit hospital beds per hundred thousand people than the U.S. does (34.7 to 3.6). That said, due to the size of China’s population, the PRC has half the overall number of ICU beds that the U.S. has. However, the U.S.’s advantages seemed not to be an impediment to have 29 times more COVID-19 infected cases (2,424,168 to 83,430) and 27 times more COVID deaths than China (123,473 to 4,634).

 

Despite the huge spending, the U.S. became the leading COVID sufferer and mitigation market leader. There are a number of reasons why this has happened:

  1. The Pandemic turned into a political issue, not a healthcare one lead by CDC that was established 77 years ago with one mission: to mitigate a spread of diseases.
  2. The White House was late to take counter-pandemic measures, including, but not limited to: stopping international travel (especially from China).
  3. The Trump administration has no consist mitigation strategy
  4. CDC challenges. During February, the CDC used erroneous PCR testing reagents and up to now they are not doing enough testing nation-wide.
  5. The federal government does not have a national lockdown authority. This authority is in the hands of the 50 states.
  6. Millions of infected low-income individuals and others, who are not covered by a medical insurance, refrained from seeking medical care when needed.

 

The USA is and will continue to be the largest COVID-19 mitigation products market because that is the only option it has, and it has the resources to invest whatever it takes to mitigate the pandemic.

 

The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen detection, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.

 

To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios:

  1. Optimistic scenario – assumes (among other things) that mass vaccination will commence by July 2021
  2. Conservative scenario – assumes (among other things) that no mass vaccination will be available until 2025

 

Why Buy this US COVID-19 Pandemic Mitigation Products Market Report?

 

A. Questions answered in this report include:

  • What is the US COVID-19 Market size and what are the forecast trends during 2020-2024?
  • What are the most attractive business opportunities?
  • What drives the customers to purchase solutions and services?
  • What are the US COVID-19 Market trends?
  • What is the 10 sub-markets size over the 2020-2024 period?
  • What are the challenges to market penetration & growth?

 

B. Detailed market analysis frameworks for each of the market sectors are provided, including:

  1. Market drivers & inhibitors
  2. Business opportunities
  3. SWOT analysis
  4. Competitive analysis for each of the 54 products and services that covers:
    1. Barriers to Entry
    2. Supplier Power
    3. Buyer Power
    4. Barriers to Substitution.
  5. Business environment
  6. The 2020-2024 market segmented into 10 submarkets

 

Table of Contents

Download TOC as PDF

Contact our sales department for additional information at: sales@hsrc.biz

Tables

 

Contact our sales department for additional information at: sales@hsrc.biz

Figures

Contact our sales department for additional information at: sales@hsrc.biz

Questions about this report?

Contact Sales: 1-571-527-1010 or Analysts: 1-202-455-0966

  • Have a question about US COVID-19 Pandemic Mitigation Products Market - 2020-2024
    Please fill out all fields in the form below and click "Submit" to send your question.
    Our representative will review your question and contact you with an answer as soon as possible.
  • This field is for validation purposes and should be left unchanged.
1
Interested in this report? Need more information?

You may also like…

X
Powered By